Target intelligence / Profile preview

Ras homolog enriched in brain (Ras protein, GTP-bound state) (RAS (GTP-bound))

Target
RAS (GTP-bound)
Molecular classification
Small GTPase, Molecular switch protein, Enzyme (GTPase), Oncogene product
01

Overview

The GTP-bound Ras protein is the **active form** of Ras, a small GTPase acting as a molecular switch in intracellular signaling. When bound to GTP, **Ras undergoes conformational changes in the switch I and II regions, enabling it to interact with downstream effector proteins (such as Raf kinase, PI3K, and Ral-GDS), thereby propagating proliferative and survival signals**[1][2][4][5][6]. The three main human isoforms—HRAS, KRAS, and NRAS—cycle between an inactive GDP-bound state and an active GTP-bound state; this cycle is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs)[1][2][5][6]. Dysregulation or mutation (particularly leading to constitutively GTP-bound, active signaling) is a **major driver of oncogenesis in many cancers**[1][2][6]. Selective inhibition of mutant GTP-bound KRAS proteins is an area of intense drug development, with clinical inhibitors now approved for certain KRAS mutations.

Other names
Ras GTPase (active state)GTP-bound RASH-Ras (GTP-bound)K-Ras (GTP-bound)N-Ras (GTP-bound)Ras oncogene protein (active state)
02

Mechanism of action

Covalent inhibition of mutant GTP-bound KRAS (e.g., G12C) blocks downstream signaling Disruption of RAS-effector interface (investigational)

03

Biological functions

Signal transductionCell proliferationCell differentiationCell cycle regulationCell migrationApoptosis
04

Disease associations

Cancer (notably various solid tumors, including pancreatic, lung, and colorectal cancer)Developmental disorders (RASopathies)
05

Safety considerations

Potential for paradoxical pathway activation (MAPK rebound)On-target, off-tumor toxicity (since RAS regulates normal cell proliferation)
06

Interacting drugs

Sotorasib (KRAS G12C inhibitor)

1 more in the full profile.

07

Biomarkers

KRAS mutation status (especially G12C, G12D, G13D, Q61 mutations)RAS activation signature/phospho-ERK (proxy)

Beyond the preview

Go deeper on Ras homolog enriched in brain (Ras protein, GTP-bound state) (RAS (GTP-bound)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ras homolog enriched in brain (Ras protein, GTP-bound state) (RAS (GTP-bound)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call